Sidebar

A new study, conducted by Jackson et al.[1], demonstrates that the intake of the prebiotic dietary fibre oligofructose alone, or in combination with the human milk oligosaccharide 2’fucosyllactose, promotes a significant increase in Bifidobacteria in the gut and can result in substantial improvements in mood[2] in healthy adults with mild to moderate feelings of anxiety and depression.

Merck, invests € 35 million in biosafety testing at its Glasgow and Stirling sites, Scotland. Biosafety testing is a critical step in the drug development

Responds to global demand for biosafety testing for drug development and commercialization
Expansion creates nearly 500 new jobs in Glasgow and Stirling
Company’s investment to boost global testing capacity now tops € 350 million since mid-2022

U.S. Food and Drug Administration accepts Soluplus® branded excipient in its program to evaluate safety and acceptability of excipients for use in clinical trials, independent from a specific New Drug Application.

Excipients (inactive ingredients) such as the Soluplus® branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients

Merck has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”.

Erbi’s differentiated 2 ml micro-bioreactor platform technology, Breez™, enables rapid lab testing for bioprocessing scale up
Allows Merck to offer full range of bioreactors, from 2ml to 2000L
Adds to company’s expertise in monoclonal antibody (mAb) process development

Page 3 of 5

Meet Our Sponsors

Latest Sponsor News

Articles Most Read

Latest News

Statistics

Articles View Hits
1673719

Who's Online

We have 79 guests and no members online